(Q35104711)

6 August 2017

1 reference

title

Antiphospholipid antibodies: discovery, definitions, detection and disease (English)

1 reference

6 August 2017

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

23 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

23 December 2023

author name string

John A. McIntyre

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12689618

23 December 2023

Dawn R. Wagenknecht

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12689618

23 December 2023

W. Page Faulk

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12689618

23 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12689618

23 December 2023

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S0163782702000486?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

https://api.elsevier.com/content/article/PII:S0163782702000486?httpAccept=text/plain

23 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Progress in Lipid Research

23 December 2023

published in

1 reference

6 August 2017

volume

42

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

176-237

1 reference

International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

International classification criteria for antiphospholipid syndrome: synopsis of a post-conference workshop held at the Ninth International (Tours) aPL Symposium

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anti-phosphatidylethanolamine (aPE) antibodies: a survey

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Biologically false positive serologic tests for syphilis; type, incidence, and cause

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

The natural history of systemic lupus erythematosus: An approach to its study through chronic biologic false positive reactors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Biologic false-positive reaction for syphilis: Massachusetts, 1954-1961.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Disseminate lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Lupus erythematosus; serologic and chemical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Different types of antiphospholipid antibodies in AIDS: a comparison with syphilis and the antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Opposite beta2-glycoprotein I requirement for the binding of infectious and autoimmune antiphospholipid antibodies to cardiolipin liposomes is associated with antibody avidity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Heterogeneity of binding reactivity to different phospholipids of antibodies from patients with systemic lupus erythematosus (SLE) and with syphilis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Landmark perspective. Diffuse collagen disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

ON THE PRESENCE IN SYPHILITIC SERUM OF ANTIBODIES TO SPIROCHETES, THEIR RELATION TO SO CALLED WASSERMANN REAGIN, AND THEIR SIGNIFICANCE FOR THE SERODIAGNOSIS OF SYPHILIS.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Systemic lupus erythematosus: a complex auto-immune disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Intrauterine death and circulating anticoagulant ("antithromboplastin")

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Demonstration of a platelet bypass mechanism in the clotting system using an acquired anticoagulant

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Platelet function and coagulation profile in lupus erythematosus. Studies in 50 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

The lupus anticoagulant. A disease marker in antinuclear antibody negative lupus that is cross-reactive with autoantibodies to double-stranded DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

THE MODE OF ACTION OF A COAGULATION INHIBITOR IN THE BLOOD OF TWO PATIENTS WITH DISSEMINATED LUPUS ERYTHEMATOSUS (DLE).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

An atypical circulating anticoagulant

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Incoagulability of the blood in systemic lupus erythematosus. A case due to hypoprothrombinemia and a circulating anticoagulant

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

The lupus anticoagulant

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Interaction between platelets and lupus anticoagulant

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Many faces of lupus anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Thrombosis in patients with the lupus anticoagulant

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

LUPUS ANTICOAGULANTS AND ANTIPHOSPHOLIPID ANTIBODIES

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies in children

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Studies on phospholipid antibodies, APC-resistance and associated mutation in the coagulation factor V gene

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Binding of autoimmune cardiolipin-reactive antibodies to heparin: a mechanism of thrombosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Current insights into the "antiphospholipid" syndrome: clinical, immunological, and molecular aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Phospholipid binding of antiphospholipid antibodies and placental anticoagulant protein

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Pathogenesis and treatment of the antiphospholipid antibody syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

The effect of membrane composition on the hemostatic balance

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti-β2-Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β2-Glycoprotein I and Induce Endothelial Activation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Competition of annexin V and anticardiolipin antibodies for binding to phosphatidylserine containing membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies and platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Effects of beta2-glycoprotein I and monoclonal anticardiolipin antibodies on extrinsic fibrinolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

The putative mechanism of thrombosis in antiphospholipid syndrome: impairment of the protein C and the fibrinolytic systems by monoclonal anticardiolipin antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Lupus anticoagulants/antiphospholipid-protein antibodies: the great imposters

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Evaluation of the minimally prolonged APTT: Passovoy factor or lupus anticoagulant?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Detection of antiphospholipid autoantibody in systemic lupus erythematosus is temperature-dependent

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Heat inactivation of serum potentiates anti-cardiolipin antibody binding in ELISA.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Heat-labile serum inhibitor of anti-phospholipid antibody binding in ELISA

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Detection of antiphospholipid antibodies in heat inactivated normal human sera

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Thrombosis, abortion, cerebral disease, and the lupus anticoagulant

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Recent advances in antiphospholipid antibody-related valvulopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

A simple radioimmunoassay to determine binding of antibodies to lipid antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

A solid phase enzyme immunoassay (ELISA) for the detection and quantitation of anticardiolipin antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

IgG but not IgM anti-phospholipid antibody binding is temperature dependent

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anticardiolipin antibodies and thrombosis: buffer's influence on the detection and quantitation of anticardiolipin antibody measured by ELISA

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anticardiolipin antibodies in systemic lupus erythematosus. Association with thrombosis if measured by ELISA with adult bovine serum as buffer rather than fetal calf serum

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Interaction of heparin with beta 2-glycoprotein I and antiphospholipid antibodies in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

The relationship between lupus anticoagulants and antibodies to phospholipid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Separation of anticardiolipin antibodies from lupus anticoagulant on a phospholipid-coated polystyrene column

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

What is the "true" antigen for antiphospholipid antibodies?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anticardiolipin antibodies: specificity and function

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anticardiolipin wet workshop report. Fifth International Symposium on antiphospholipid antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Alteration of the aPA ELISA by UV exposure of polystyrene microtiter plates

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Interlaboratory inconsistencies in detection of anticardiolipin antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Interlaboratory variation in antiphospholipid antibody testing

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Inter-assay variation in antiphospholipid antibody testing.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Regulation of cardiolipin biosynthesis in the heart

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Cardiolipin is a normal component of human plasma lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Cardiolipin on the surface of apoptotic cells as a possible trigger for antiphospholipids antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Influence of degraded phosphatidylserine on binding of antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

c-Abl tyrosine kinase binds and phosphorylates phospholipid scramblase 1

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies and recurrent pregnancy loss: correlation between the activated partial thromboplastin time and antibodies against phosphatidylserine and cardiolipin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Monoclonal IgM antiphosphatidylserine antibody reacts against cytoskeleton-like structures in cultured human umbilical cord endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Monoclonal antiphosphatidylserine antibody reactivity against human first-trimester placental trophoblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Interaction of heparin with antiphospholipid antibodies (APA) from the sera of women with recurrent pregnancy loss (RPL)

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

A model for the antiphospholipid antibody syndrome: monoclonal antiphosphatidylserine antibody induces intrauterine growth restriction in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

The pathogenic role of anti-phosphatidylserine antibodies: active immunization with the antibodies leads to the induction of antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Induction of high levels of anticardiolipin antibodies in mice by immunization with beta 2-glycoprotein I does not cause fetal death

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

The effect of human anticardiolipin antibodies on murine pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Variable effects on murine pregnancy of immunoglobulin G fractions from women with antiphospholipid antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti-cardiolipin antibodies in pregnant naive BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Defective maternal-fetal interaction in a murine autoimmune model

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Sera from women with histories of repeated pregnancy losses cause abnormalities in mouse peri-implantation blastocysts.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Midfollicular anticardiolipin and antiphosphatidylserine antibody titers do not correlate with in vitro fertilization outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antibodies to beta2 glycoprotein I are associated with in vitro fertilization implantation failure as well as recurrent miscarriage: results of a prevalence study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Association of antibodies to beta2-glycoprotein 1 with pregnancy loss and pregnancy-induced hypertension: a prospective study in low-risk pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies in patients with preeclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies in women at risk for preeclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Down-regulation of maternal antiphospholipid antibodies during early pregnancy and pregnancy outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Serum levels of anticardiolipin antibodies are pathologically increased after active immunization of patients with recurrent spontaneous abortion

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Marked variation in antiphospholipid antibodies during pregnancy: relationships to pregnancy outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Clearance of antiphospholipid antibodies in pregnancies treated with heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

The influence of antiphospholipid antibodies on the pregnancy outcome of patients with recurrent spontaneous abortion

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphosphatidylserine antibodies in patients with autoimmune diseases and HIV-infected patients: effects of Tween 20 and relationship with antibodies to beta2-glycoprotein I

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphosphatidylserine antibodies are elevated in normal tension glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Association of antiphosphatidylserine/prothrombin autoantibodies with HLA class II genes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Molecular analysis of major histocompatibility complex alleles associated with the lupus anticoagulant

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

The prevalence of antibodies to anionic phospholipids in patients with the primary antiphospholipid syndrome, systemic lupus erythematosus and their relatives and spouses

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Ultrastructural localization of monoclonal antiphospholipid antibody binding to rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Placental anticoagulant proteins: isolation and comparative characterization four members of the lipocortin family

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Annexin V is critical in the maintenance of murine placental integrity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anti-annexin V antibodies in patients with early pregnancy loss or implantation failures

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphosphatidylserine antibody removes annexin-V and facilitates the binding of prothrombin at the surface of a choriocarcinoma model of trophoblast differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Phosphatidyl choline is recognized by a series of Ly-1+ murine B cell lymphomas specific for erythrocyte membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Restricted immunoglobulin variable region gene usage by normal Ly-1 (CD5+) B cells that recognize phosphatidyl choline

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Autoantibodies to phosphatidylcholine. The murine antibromelain RBC response

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid Antibodies Reactive with Bromelain-Treated Mouse Erythrocytes in Mice, Rats and Rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Acyl chain length effects related to glycosphingolipid crypticity in phospholipid membranes: probed by 2H-NMR

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Hemolytic anemia related to an IgM autoantibody to phosphatidylcholine that binds in vitro to stored and to bromelain-treated human erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Control of early viral and bacterial distribution and disease by natural antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

The characteristics of bronchoalveolar lavage from a patient with antiphospholipid syndrome who developed acute respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Promotion of platelet aggregation by sera from brucellosis patients with antiphosphatidylcholine antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Characterization of anti-phosphatidylcholine polyreactive natural autoantibodies from normal human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Homocysteine as a cardiovascular risk factor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Spectrum of antiphospholipid antibodies (aPL) in patients with cerebrovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Transfer of experimental antiphospholipid syndrome by bone marrow cell transplantation. The importance of the T cell

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Induction of experimental anti-phospholipid syndrome associated with SLE following immunization with human monoclonal pathogenic anti-DNA idiotype

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid-protein antibodies and ischemic stroke: not just cardiolipin any more.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anticardiolipin antibodies: isotype distribution and phospholipid specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Certain autoantibodies to phosphatidylethanolamine (aPE) recognize factor XI and prekallikrein independently or in addition to the kininogens

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Syndrome des antiphospholipides avec anticorps antiphosphatidyléthanolamine isolés : à propos de 20 cas

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

The structural specificity of anti-phospholipid antibodies in autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Phospholipid in the hexagonal II phase is immunogenic: evidence for immunorecognition of nonbilayer lipid phases in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibody production during Mediterranean spotted fever.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Association of lupus anticoagulant with antibody against phosphatidylserine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Phospholipid binding plasma proteins required for antiphospholipid antibody detection--an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Evaluation of the clinical and laboratory associations of antiphosphatidylethanolamine antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphosphatidylethanolamine antibodies in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Incidence of antiphospholipid antibodies in patients with monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antibodies to phosphatidylethanolamine in antiphospholipid syndrome and systemic lupus erythematosus: their correlation with anticardiolipin antibodies and beta 2 glycoprotein-I plasma levels

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Microtitre plate and assay buffer alter detection of antiphosphatidylethanolamine antibodies in lupus anticoagulant positive plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Development of the hemostatic system in the neonate and young infant

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Advantage of using both anionic and zwitterionic phospholipid antigens for the detection of antiphospholipid antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Lysophosphatidylethanolamine is the antigen to which apparent antibody to phosphatidylethanolamine binds

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Influence of the phosphatidylethanolamine (PE) and bovine serum origins on anti-PE antibody detection by ELISA.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Specific antiphospholipid antibodies as a predictive variable in patients with recurrent pregnancy loss

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Recurrent abortion and moderate or strong antiphospholipid antibody production

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Autoantibodies in women with primary recurrent spontaneous abortion of unknown etiology

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Autoantibodies to phospholipids and nuclear antigens in non-pregnant and pregnant Colombian women with recurrent spontaneous abortions

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies associated with implantation failure after IVF/ET.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Criteria for antiphospholipid syndrome: early pregnancy loss, fetal loss, or recurrent pregnancy loss?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies are a risk factor for early renal allograft failure

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies in heart transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Risk of early renal allograft failure is increased for patients with antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

The pre-conditioning incidence of antiphospholipid antibodies is not significantly increased in patients with bone marrow transplant-related organ dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies are a risk factor for early renal allograft failure: isolation of antiphospholipid antibodies from a thrombosed renal allograft

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Autoantibodies to kininogen-phosphatidylethanolamine complexes augment thrombin-induced platelet aggregation.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies in left-ventricular assist system recipients after exposure to topical bovine thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Increased incidence of antiphospholipid antibodies in left ventricular assist system recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Phospholipid antibodies in alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: a unifying 'membrane stress syndrome' hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Henoch-Schönlein purpura and stroke: antiphosphatidylethanolamine antibody in CSF and serum

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Transbilayer movement of phospholipids in red cell and platelet membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

A novel peptide probe for studying the transbilayer movement of phosphatidylethanolamine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Exposure of phosphatidylethanolamine on the surface of apoptotic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Redistribution of phosphatidylethanolamine at the cleavage furrow of dividing cells during cytokinesis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

An essential role for a membrane lipid in cytokinesis. Regulation of contractile ring disassembly by redistribution of phosphatidylethanolamine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies in sickle cell disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Hemostasis and fibrinolysis in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Allograft membranous glomerulonephritis and renal-vein thrombosis in a patient with a lupus anticoagulant factor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Thrombotic microangiopathy related to anticardiolipin antibody in a renal allograft

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibody syndrome and posttransplant renal thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Renal transplantation in anticardiolipin antibody-positive lupus erythematosus patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibody syndrome in renal transplantation: occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Kidney retransplants after initial graft loss to vascular thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anticardiolipin antibodies and hepatic artery thrombosis after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Graft loss and the antiphospholipid syndrome following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Immunosuppressive treatment in a heart transplantation candidate with antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Results of extended bridge to transplantation: window into the future of permanent ventricular assist devices

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting heart transplantation. Fluorescence-activated cell sorter analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Changes in platelet activation associated with left ventricular assist system placement

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Left ventricular assist system recipients exposed to bovine thrombin preparations have a higher frequency of antiphospholipid antibodies than nonexposed recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Immunochemical analysis of polyspecific antibodies in patients exposed to bovine fibrin sealant

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies in vascular surgery patients. A cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Prospective comparison of infrainguinal bypass grafting in patients with and without antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antibodies to cardiolipin may increase the risk of failure of peripheral vein bypasses

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anticardiolipin antibodies and thromboembolism after BMT.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Autologous peripheral blood stem and progenitor (CD34+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Disappearance of lupus anticoagulant after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

High levels of antiphospholipid antibodies are associated with cytomegalovirus infection in unrelated bone marrow and cord blood allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

New developments in viral peptides and APL induction

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Gastrointestinal vasculitis in autoimmune-prone (NZW X BXSB)F1 mice: association with anticardiolipin autoantibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Effect of bone marrow transplantation on antiphospholipid antibody syndrome in murine lupus mice

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Systemic exposure to irradiated apoptotic cells induces autoantibody production

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

The immune response to apoptotic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Apoptosis in the human uterine endometrium during the menstrual cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anticardiolipin antibodies in clinical conditions associated with a risk of thrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Anti-cardiolipin antibodies (IgG and IgA) in women with recurrent fetal loss correlate to clinical and serological characteristics of SLE.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Clinical significance of immunoglobulin A versus immunoglobulins G and M anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Correlation with thrombosis, thrombocytopenia, and recurrent abortion

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

IgA antiphospholipid antibodies in HTLV-1-associated tropical spastic paraparesis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Significance of IgA antiphospholipid antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Testing for the antiphospholipid syndrome: importance of IgA anti-beta 2-glycoprotein I

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Frequency and specificities of antiphospholipid antibodies (aPL) in volunteer blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Purification of antiphospholipid antibodies using a new affinity method

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Use of antithrombotic agents during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

1 reference

7 January 2021

Antimalarials--the 'real' advance in lupus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Intravenous immunoglobulin therapy of antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

Antiphospholipid antibodies, ischemic stroke in young adults, and calcium supplementation: a hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900048-6

7 January 2021

The occurrence of circulating anticoagulants in patients with syphilitic and biologically false positive antilipoidal antibodies

16

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

A new type of coagulation inhibitor

23 December 2023

41

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Acquired Inhibitors in Nonhemophilic Patients

23 December 2023

42

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Is there a phospholipid specificity of lupus anticoagulants (LAC) in patients with autoimmune and drug induced LAC?

23 December 2023

48

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Acquired inhibitors of blood coagulation

23 December 2023

66

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Antiphospholipid-thrombosis syndromes

23 December 2023

79

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus

23 December 2023

88

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Heparin and pregnancy in women with a history of repeated miscarriages

23 December 2023

181

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

The association of antiphospholipid antibodies with severe preeclampsia

23 December 2023

203

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

White blood cell immunization and anticardiolipin antibody levels in women with recurrent miscarriages

23 December 2023

207

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Autoantibodies against mouse bromelain-modified RBC are specifically inhibited by a common membrane phospholipid, phosphatidylcholine

23 December 2023

232

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Antibodies against phospholipids and oxidized LDL in alcoholic patients

23 December 2023

244

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Anti-phosphatidylinositol antibodies and their determination using our ELISA method

23 December 2023

252

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Prevalence and clinical significance of antiphospholipid antibodies to noncardiolipin antigens in systemic lupus erythematosus

23 December 2023

256

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Phospholipid specificity of autoimmune and drug induced lupus anticoagulants; association of phosphatidylethanolamine reactivity with thrombosis in autoimmune disease

23 December 2023

268

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus

23 December 2023

272

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis

23 December 2023

275

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Plasma reactivity to hexagonal II phase phosphatidylethanolamine is more frequently associated with lupus anticoagulant than with antiphosphatidylethanolamine antibodies

23 December 2023

277

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies detected by ELISA. II. Kininogen reactivity

23 December 2023

281

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Patterns of anti-phospholipid antibody specificities

23 December 2023

300

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Lupus anticoagulant and thrombosis of kidney allograft vessels

23 December 2023

334

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Recurrent renal thrombotic angiopathy after kidney transplantation in two patients with primary antiphospholipid syndrome (PAPS)

23 December 2023

335

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Relative risk of post-transplant renal thrombosis in patients with antiphospholipid antibodies

23 December 2023

337

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Antiphospholipid antibodies causing positive flow crossmatches and interfering with T-cell immunophenotyping

23 December 2023

357

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Hepatic veno-occlusive disease in a patient with lupus anticoagulant after allogeneic bone marrow transplantation

23 December 2023

358

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Lupus inhibitors following bone marrow transplant

23 December 2023

359

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

Association of quantitative anticardiolipin antibody levels with fetal loss and time of loss in systemic lupus erythematosus

23 December 2023

373

1 reference

https://api.crossref.org/works/10.1016/S0163-7827(02)00048-6

23 December 2023

Identifiers

1 reference

6 August 2017

1 reference